首页> 外文期刊>The Lancet >Rheumatoid arthritis
【24h】

Rheumatoid arthritis

机译:类风湿关节炎

获取原文
获取原文并翻译 | 示例
           

摘要

Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor outcomes such as high disease activity, presence of autoantibodies, and early joint damage. Treatment algorithms involve measuring disease activity with composite indices, applying a treatment-to-target strategy, and use of conventional, biological, and newz non-biological disease-modifying antirheumatic drugs. After the treatment target of stringent remission (or at least low disease activity) is maintained, dose reduction should be attempted. Although the prospects for most patients are now favourable, many still do not respond to current therapies. Accordingly, new therapies are urgently required. In this Seminar, we describe current insights into genetics and aetiology, pathophysiology, epidemiology, assessment, therapeutic agents, and treatment strategies together with unmet needs of patients with rheumatoid arthritis.
机译:类风湿关节炎是一种慢性炎症性关节疾病,可导致软骨,骨骼损伤以及残疾。早期诊断是获得最佳治疗成功的关键,特别是对于那些具有不良后果(如疾病活动率高,自身抗体存在和早期关节损伤)的危险因素具有明确特征的患者。治疗算法包括使用综合指数来测量疾病活动,采用针对治疗的策略以及使用常规,生物和新型的非生物疾病修饰性抗风湿药。在维持严格缓解(或至少低疾病活性)的治疗目标后,应尝试降低剂量。尽管大多数患者的前景现在是有利的,但许多患者仍然对当前的疗法没有反应。因此,迫切需要新的疗法。在本次研讨会中,我们将介绍有关遗传学和病因学,病理生理学,流行病学,评估,治疗药物和治疗策略的最新见解,以及类风湿关节炎患者的未满足需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号